Go to content
UR Home

MGMT gene silencing and benefit from temozolomide in glioblastoma

Hegi, Monika E., Diserens, Annie-Claire, Gorlia, Thierry, Hamou, Marie-France, de Tribolet, Nicolas, Weller, Michael, Kros, Johan M., Hainfellner, Johannes A., Mason, Warren, Mariani, Luigi, Bromberg, Jacoline E. C., Hau, Peter, Mirimanoff, René O., Cairncross, J. Gregory, Janzer, Robert C. and Stupp, Roger (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine 352 (10), pp. 997-1003.

Full text not available from this repository.

at PubMed

at publisher (via DOI)


Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.

Export bibliographical data

Item type:Article
Institutions:Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT)
Identification Number:
15938011PubMed ID
Antineoplastic Agents, Alkylating/therapeutic useMESH
Brain Neoplasms/radiotherapyMESH
Chemotherapy, AdjuvantMESH
DNA MethylationMESH
Dacarbazine/therapeutic useMESH
Disease-Free SurvivalMESH
Gene SilencingMESH
O(6)-Methylguanine-DNA Methyltransferase/geneticsMESH
Polymerase Chain ReactionMESH
Promoter Regions, GeneticMESH
Randomized Controlled Trials as TopicMESH
Survival AnalysisMESH
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Unknown
Item ID:29305
Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons